These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39258877)

  • 1. Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa.
    Lodise TP; Obi EN; Watanabe AH; Yucel E; Min J; Nathanson BH
    J Antimicrob Chemother; 2024 Nov; 79(11):2954-2964. PubMed ID: 39258877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and emergence of resistance of
    Hareza DA; Cosgrove SE; Bonomo RA; Dzintars K; Karaba SM; Hawes AM; Tekle T; Simner PJ; Tamma PD
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0090724. PubMed ID: 39230311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
    Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
    Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
    J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
    Almangour TA; Ghonem L; Alassiri D; Aljurbua A; Al Musawa M; Alharbi A; Almohaizeie A; Almuhisen S; Alghaith J; Damfu N; Aljefri D; Alfahad W; Khormi Y; Alanazi MQ; Alsowaida YS
    Antimicrob Agents Chemother; 2023 Aug; 67(8):e0040523. PubMed ID: 37404159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftolozane/tazobactam and ceftazidime/avibactam antimicrobial activity against clinically relevant gram-negative bacilli isolated in Mexico.
    Martínez-Miranda R; Gastélum-Acosta M; Guerrero-Estrada P; Ayala-Figueroa RI; Osuna-Álvarez LE
    Gac Med Mex; 2020; 156(6):592-597. PubMed ID: 33877120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
    Evans SR; Tran TTT; Hujer AM; Hill CB; Hujer KM; Mediavilla JR; Manca C; Domitrovic TN; Perez F; Farmer M; Pitzer KM; Wilson BM; Kreiswirth BN; Patel R; Jacobs MR; Chen L; Fowler VG; Chambers HF; Bonomo RA;
    Clin Infect Dis; 2019 May; 68(11):1823-1830. PubMed ID: 30239599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
    Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
    Ortiz de la Rosa JM; Nordmann P; Poirel L
    J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
    Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G
    J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approach to the Treatment of Patients with Serious Multidrug-Resistant Pseudomonas aeruginosa Infections.
    O'Donnell JN; Bidell MR; Lodise TP
    Pharmacotherapy; 2020 Sep; 40(9):952-969. PubMed ID: 32696452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation.
    Amore D; Pecoraro Y; Carillo C; Russo G; Poggi C; Anile M; Pagini A; Bassi M; Cagnetti S; Mottola E; D'Agostino FG; Vannucci J; Mantovani S; Pugliese F; De Giacomo T; Rendina EA; Venuta F; Diso D
    Transplant Proc; 2020 Jun; 52(5):1605-1607. PubMed ID: 32209238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
    Maraolo AE; Cascella M; Corcione S; Cuomo A; Nappa S; Borgia G; De Rosa FG; Gentile I
    Expert Rev Anti Infect Ther; 2017 Sep; 15(9):861-871. PubMed ID: 28803496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.